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Introduction
Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm of transformed 
pluripotent haematopoietic progenitors. The Philadelphia (Ph) chromosome that results 
from the balanced translocation t(9;22)(q11;q34) fusing with the ABL proto-oncogene on 
chromosome 9 and the BCR gene on chromosome 22 is the cytogenetic hallmark of the 
disease. Chronic myeloid leukaemia is a three-phase disease. Most patients present in 
the chronic phase (CP), and progress, years later, to the blast phase (BP), either directly 
or through an intermediate accelerated phase (AP). Bone marrow transplantation (BMT) 
is the only curative option but this is applicable only to young patients with available 
histocompatible donors and carries significant morbidity and mortality. Hydroxyurea and 
busulfan control myeloproliferation but not natural progression of the disease. Although 
interferon-α (IFN-α) prolongs survival, the cytogenetic response rate is low and there are 
problems with poor drug tolerance.
 Imatinib mesylate (Glivec or Gliveec, Novartis Pharmaceuticals, Basel, Switzerland) 
is the tyrosine kinase inhibitor (TKI) that inhibits the BCR-ABL oncoprotein. It is more 
effective than IFN-α, and safer than allogenic stem cell transplantation for controlling 
CML.1 After 5 years, the best rates of complete haematologic response (CHR), complete 
cytogenetic response (CCgR), and overall survival were 97%, 87% and 89% respectively, 
which are higher than any of the conventional therapies for CML.2,3 It has been approved 
by the Hong Kong Hospital Authority as a first-line agent for the treatment of CML since 
2005.
 Although the majority of CML patients show haematological responses, approximately 
3% of CP, 20% of AP, and 50% of BP patients never respond.2,4,5 Moreover, responders 
relapse at a rate of 0.4 to 5.5% annually.2 Mechanisms contributing to imatinib resistance 
are heterogeneous, which can be BCR-ABL–dependent, such as ABL kinase domain (KD) 
point mutation,6 BCR-ABL gene amplification,6 and BCR-ABL–independent mechanisms 
such as activation of alternative kinases7 and changes in drug influx (hOCT1) or efflux 
(MDR1) proteins.8 Of these mechanisms, BCR-ABL KD point mutation is the most common 
and the best understood.9
 Imatinib binds specifically to the ATP-binding pocket on the catalytic domain of 
the inactive-conformation BCR-ABL oncoprotein.10 Point mutations that change the 
amino acid of the contact site or the specific KD conformation to which imatinib binds 
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Imatinib is the standard treatment for chronic myeloid leukaemia. BCR-ABL kinase domain 
mutation is the commonest mechanism implicated in imatinib resistance. In in-vitro studies, 
kinase domain mutations are variably resistant to second-line agents. We performed BCR-ABL 
kinase domain mutational studies in 25 patients in five institutions who failed imatinib and 
were treated with either nilotinib or dasatinib, to see if their mutational status would predict 
their clinical responses. Kinase domain mutations involving 11 amino acid substitutions were 
found in 12 (48%) patients. Most patients showed single kinase domain mutations. There 
was some concordance between reported drug sensitivity patterns and patient responses. 
Discordant responses could be related to drug dosage variations and unknown BCR-ABL 
independent mechanisms. The response prediction for patients with multiple kinase domain 
mutations was challenging and their mutational patterns could change after tyrosine kinase 
inhibitor therapy. Although BCR-ABL kinase domain mutational analysis has limitations as a 
means of predicting the clinical response to second-line tyrosine kinase inhibitors, it helps 
inform therapy decisions in the management of chronic myeloid leukaemia after imatinib 
failure.
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the KD mutations was studied.
Methods
Samples were collected from CML patients resistant 
to imatinib or other TKIs between October 2006 and 
September 2008. BCR-ABL KD mutational assays 
were conducted in the Queen Mary Hospital and 
the Hong Kong Sanatorium and Hospital. The group 
included patients referred from five regional tertiary 
centres in Hong Kong (Queen Mary Hospital, Hong 
Kong Sanatorium and Hospital, Tuen Mun Hospital, 
Princess Margaret Hospital, and Pamela Youde 
Nethersole Eastern Hospital).
 Total RNA was extracted from the peripheral 
blood using a QIAamp RNA Blood Kit (Qiagen, 
Hilden, Germany). cDNA was then synthesised using 
SuperScript III Reverse Transcriptase (Invitrogen, 
Carlsbad [CA], US). The BCR-ABL KD was amplified 
by polymerase chain reaction (PCR), as previously 
described, using the same set of primers.23 Polymerase 
chain reaction products were sequenced directly 
using the BigDye Terminator v3.1 cycle sequencing 
kit (Applied Biosystems, Foster City, US). The DNA 
sequences of the PCR products were then aligned 
against the reference sequence (GenBank accession 
number M14752) of the ABL KD using Mutation 
Surveyor software (Version 2.61, SoftGenetics, LLC, 
State College, US). Any presence of a mutation in 
a sample had to be confirmed in a second sample 
collected at the same time, if available, or in the same 
sample by repeated analysis.
 Chronic phase, AP, and BP were defined 
according to the World Health Organization 
classification.24 A CHR was defined as a white blood 
cell count of less than 10 000/mL, a platelet count of 
less than 450 000/mL, a basophil count of less than 5%, 
an absence of immature granulocytes in peripheral 
blood, and absence of splenic enlargement. A major 
cytogenetic response (MCgR) was defined as ≤35% 
Ph+ metaphase of 20 marrow metaphases examined 
using conventional cytogenetics, or ≤35% Ph+ nuclei 
of 300 interphase cells examined with fluorescence in-
situ hybridisation using peripheral blood or marrow 
samples. A CCgR was defined as 0% Ph+ metaphase 
or interphase nuclei. A major molecular response 
(MMR) was defined as ≤0.1% BCR-ABL/ABL by real-
time quantitative PCR (RQ-PCR) on the international 
scale (BCR-ABLIS). A complete molecular response 
(CMR) was defined as an undetectable level of BCR-
ABL transcript by RQ-PCR. With imatinib, primary 
haematologic resistance was defined as a failure 
to reach CHR after 3 months of treatment. Primary 
cytogenetic resistance was defined as a failure to 
reach MCgR after 18 months. Loss of MCgR, loss 
of CHR, and progression to AP or BP constituted 
secondary or acquired resistance.
 Many patients cannot tolerate the standard 
attenuate its inhibitory property.11,12 More than 90 
mutations have been reported, most of them in 
four regions: the ATP-binding loop (P-loop), the 
contact site, the SH2-binding site (activation loop), 
and the catalytic domain.13 Most mutations involve 
amino acid substitutions at a few residues (P-loop: 
E255/V, M244V, G250E, Y253H/F; drug contact site: 
T315I, F317L; catalytic domain: M351T, F359V).14 They 
vary in the degree of drug resistance and clinical 
significance.15,16 Some mutants may still be sensitive 
to a higher imatinib concentration,17,18 while others 
that are highly resistant are only inhibited by more 
potent second-generation TKIs.19
 Nilotinib (Tasigna, Novartis Pharmaceuticals, 
Basel, Switzerland) and dasatinib (Sprycel, Bristol-
Myers Squibb, Princeton [NJ], US) are the second-
generation TKIs approved by the Food and Drug 
Administration for treatment of imatinib-resistant 
and -intolerant CP and AP CML. Only dasatinib is 
approved for treatment of blastic disease. Nilotinib 
is 30 times, and dasatinib is 300 times more potent 
than imatinib.19 Dasatinib differs from imatinib and 
nilotinib in that it binds to both active and inactive 
conformations of ABL.19 It is also a dual kinase 
inhibitor active against both ABL and Src family 
kinases such as Lyn.19 In in-vitro studies, most KD 
mutants show different sensitivities to nilotinib and 
dasatinib except for T315I, which is highly resistant 
to both agents.20 Mutations resistant to one TKI agent 
may still be responsive to others.21,22 Therefore, when 
CML fails to respond to TKI therapy, a mutational 
analysis may help guide the decision to switch to 
alternative TKI agents or another therapy. In a cohort 
of CML patients failing imatinib and other TKIs, we 
performed a retrospective analysis for BCR-ABL KD 
mutation before further treatment with alternative 
agents. The relationship between the response and 
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doses of dasatinib (100 mg/day) and nilotinib (800 mg/
day). Haematological toxicity, fluid retention, and rash 
were among the commonest side-effects leading to 
dosage reduction and therapy interruption. The mean 
TKI doses tolerated by patients were considered when 
interpreting the responses of KD mutants. Tyrosine 
kinase inhibitor mean dose intensity was calculated 
by averaging the total dose taken throughout the 
therapy period until disease progression, loss of 
response or latest follow-up. Days when TKI was not 
given were calculated as a percentage of total therapy 
duration.
Results
Patient characteristics and kinase domain 
mutations
Twenty-five patients (13 CP, 7 AP of which 2 were in 
second CP at the time of salvage, and 5 BP of which 
1 was in second CP at the time of salvage) were 
assayed for BCR-ABL KD mutation before their latest 
salvage TKI therapy (18 before dasatinib and 7 before 
nilotinib). Two had relapses after BMT. All patients 
were haematologically or cytogenetically resistant 
to imatinib, and two were also intolerant, preventing 
escalation to the standard dose (Table 1). Before 
dasatinib salvage, 11 had failed nilotinib treatment, 
and before nilotinib salvage, two had failed dasatinib 
or bosutinib.
 Kinase domain point mutations resulting in 
substitution of 11 amino acid residues (M244V=1, 
L248V=1, G250E=1, Y253H=1, E255K=4, E279K=1, 
T315I=2, F317L=2, M351T=1, F359V=2, E459K=1) were 
found in 12 (48%) patients (Table 2). Most patients 
showed single KD mutations. Multiple KD mutations 
were found in four patients after sole imatinib therapy 
(2 CP and 2 BP).
Relationship between in-vitro drug sensitivities 
of kinase domain mutants and their clinical 
responses
In-vitro sensitivity to TKI of various KD mutants was 
assessed in terms of their IC50 values (Table 3). IC50 
is the concentration of TKI required to inhibit 50% 
of Ba/F3 cell viability after transfection with BCR-ABL 
mutants.27 We assessed whether the reported in-vitro 
drug sensitivity pattern of KD mutations can be used 
to predict clinical responses (Tables 2 and 3). IC50 
values (Table 3) used in our study are adopted from 
previous publications by O’Hare et al (2005)20 and 
Redaelli et al (2009).27
 Two patients had F359V mutations (D1, D2). Both 
had failed previous imatinib and nilotinib therapy. 
After dasatinib, significant responses with MMR 
achieved at 18 months in D1 and CMR at 24 months 
in D2. The current starting dose recommended for 
dasatinib is 100 mg/day; 70 mg twice daily was the 
dose used in drug approval studies.28,29 Patient D1 was 
only able to tolerate a lower dose of dasatinib (dose 
intensity, 55 mg/day). The high in-vitro sensitivity 
of F359V to dasatinib may allow dosage reduction 
for poorly tolerant patients without compromising 
clinical responses.
 None of the patients with the highly resistant 
T315I mutant (D4, D17) responded to dasatinib (IC50 
75x). The patient with blastic disease (D17) had two 
other concomitant dasatinib-resistant mutants (E255K 
and F317L). Mutants E279K, M244V, and L248V were 
moderately resistant to nilotinib in vitro. Patients 
N5 and N6 with advanced disease harbouring these 
mutants were unresponsive to nilotinib, despite a 
nilotinib dose of 400 to 800 mg/day.
 A single E255K mutation was observed in three 
patients (D10, D11, and D16). All had advanced disease 
and two had failed previous nilotinib therapy. After 
dasatinib, durable CHR and CCgR were achieved 
in patient D11, even though the E255K mutation is 
regarded as dasatinib-resistant, based on reported 
IC50 values. This patient had a higher dasatinib 
dose intensity (106 vs 31-52 mg/day) and fewer days 
off-medication (0% vs 56-61%) than the two non-
responders who progressed to BP subsequently.
 A single F317L mutation was seen in one patient 
(D3). This mutation is resistant to dasatinib in vitro 
and in vivo.20,30,31 In a study of 12 patients with baseline 
F317L mutations, only three showed a transient 
haematological response to dasatinib.31 Surprisingly, 
our patient with F317L responded dramatically and 
achieved MMR. The prescribed dose of dasatinib 
was not higher than that in published study (140 mg/
day).29 The reason for this patient’s response is not 
clear, though one may speculate effect of dasatinib 
inhibition on kinases other than BCR-ABL such as 
Lyn which may be oncogenically more active and 
addictive in the leukaemia cells of some patients 
than in others.7 In terms of in-vitro sensitivity, F317L 
should be more sensitive to nilotinib.20
Indications for second-line TKI therapy No. of 
patients
Primary resistance
Haematologic 4
Cytogenetic 13
Secondary resistance
Progression to accelerated phase/blast phase 5
Loss of complete haematologic response 1
Loss of complete cytogenetic response -
Intolerant to imatinib 2
Total 25
TABLE 1. Indications of latest salvage tyrosine kinase inhibitor 
(TKI) therapy for patients in the present study
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Patient No. Prior TKI therapy Disease phase at current TKI Indication for current 
TKI
Mutation status before current 
TKI
Best haematologic 
response†
Cytogenetic/molecular response‡ TKI mean dose 
intensity (mg/day)§
Days not on TKI (% 
of total duration)
Subsequent progression
D1 Imatinib CP No MCgR F359V CHR CCgR equivalence 55 1% No progression in CHR (22 months)
Nilotinib BCR-ABL/ABL: 44.38% (0 month) to MMR (18 months)
D2 Imatinib CP No CHR F359V Achieved CHR CCgR 114 0% No progression in CHR (27 months)
Nilotinib BCR-ABL/ABL: 69% (0 month) to CMR (24 months)
D3 Imatinib CP Loss of CHR F317L Achieved CHR CCgR 140 0% No progression in CHR (27 months)
BCR-ABL/ABL: 65.3% (0 month) to MMR (24 months)
D4 Imatinib CP No CHR T315I No CHR No MCgR 103 6% No progression in CHR (11 months)
BCR-ABL/ABL: 81.5% to 28.2% (10 months)
N1 Imatinib CP No MCgR Y253H CHR MCgR 443 0% No progression in CHR (25 months)
E459K BCR-ABL/ABL: 28.7% (0 month) to 1.6% (25 months)
N2 Imatinib CP No CHR G250E CHR No MCgR (8 months) 456 6% Loss of CHR (8 months)
M351T
D5 Imatinib CP No MCgR No mutation CHR No MCgR equivalence 55 20% MUD-BMT
Nilotinib BCR-ABL/ABL: 27.2% (0 month) to 35.7% (3 months)
D6 Imatinib CP No MCgR No mutation CHR No MCgR 25 26% No progression in CHR (22 months)
Nilotinib BCR-ABL/ABL: 69.8% (0 month) to 11.6% (22 months)
D7 Imatinib CP No MCgR No mutation CHR NE 69 0% Progression to BP (3 months)
Nilotinib
D8 Imatinib CP No MCgR No mutation CHR No MCgR equivalence 53 10% No progression in CHR (28 months)
Nilotinib BCR-ABL/ABL: 22% (0 month) to 15.1% (22 months)
D9 Imatinib CP No MCgR No mutation CHR MCgR 35 5% No progression in CHR (26 months)
BCR-ABL/ABL: 216% (0 month) to 11.6% (18 months)
N3 Imatinib CP No MCgR No mutation CHR CCgR equivalence 534 7% No progression in CHR (11 months)
Bosutinib BCR-ABL/ABL: 45.2% (0 month) to 0.46% (8 months)
N4 Imatinib CP No MCgR No mutation CHR No MCgR equivalence 194 9% No progression in CHR (9 months)
Dasatinib BCR-ABL/ABL: 24.96% (2 months) to 16.3% (7 months)
Bosutinib
D10 Imatinib AP No MCgR E255K CHR No MCgR 52 61% Progression to BP (7 months)
Nilotinib BCR-ABL/ABL: 94.2% (0 month) to 57.5% (6 months)
D11 Imatinib AP Progression to AP E255K Achieved CHR CCgR 106 0% No progression in CHR (24 months)
BCR-ABL/ABL: 197.8% to 0.2% (24 months)
N5 Imatinib AP Progression to AP E279K No CHR No CHR (3 months) 800 0% No CHR (3 months)
D12 Imatinib AP Progression to AP No mutation Achieved CHR MCgR equivalence 104 0% Progression to BP (5 months)
BCR-ABL/ABL: 26% (0 month) to 9% (3 months)
D13 Imatinib AP Progression to AP No mutation Achieved CHR CCgR equivalence 44 11% No progression in CHR (27 months)
BCR-ABL/ABL: 322% (0 month) to MMR (27 months)
D14 Imatinib Post-allo-SCT AP in second CP No MCgR No mutation CHR No MCgR 23 18% No progression in CHR (24 months)
Nilotinib BCR-ABL/ABL: 229% (0 month) to 38.7% (24 months)
D15 Imatinib Post-allo-SCT AP in second CP No CHR No mutation Achieved CHR No MCgR 49 9% No progression in CHR (23 months)
Nilotinib BCR-ABL/ABL: 52.3% (0 month) to 10.9% (23 months)
D16 Imatinib BP No MCgR E255K HR No MCgR 31 56% Loss of HR with blastic relapse (7 months)
Nilotinib BCR-ABL/ABL: 64.2% (0 month) to 27.5% (6 months)
D17 Imatinib BP No CHR E255K No HR NE 86 9% Persistent BP (3 months)
T315I
F317L
N6 Imatinib BP Progression to BP M244V No HR NE 400 0% Persistent BP (3 months)
L248V
D18 Imatinib BP No HR No mutation No HR NE 93 0% Persistent BP (2 weeks)
Nilotinib
N7 Imatinib BP in second CP No MCgR No mutation CHR NE 141 24% Progression to BP (4 months)
TABLE 2. Summary of patients included in this study*
* allo-SCT denotes allogenic stem cell transplantation, BP blast phase, CCgR complete cytogenetic response, CHR complete haematologic response, CP chronic 
phase, D patients on dasatinib therapy, HR haematological response, MCgR major cytogenetic response, MMR major molecular response, MUD-BMT marrow 
unrelated donor–bone marrow transplantation, N patients on nilotinib therapy, NE not evaluated, and TKI tyrosine kinase inhibitor
† Achieved CHR refers to CHR achieved in a patient without CHR at baseline
‡ Cytogenetic response was assessed using fluorescence in-situ hybridisation. For patients monitored by real-time quantitative polymerase chain reaction, level 
of cytogenetic response was estimated from BCR-ABL/ABL ratio25,26: No MCgR equivalence=BCR-ABL/ABL>12.7% (BCR-ABLIS>10%); MCgR equivalence=BCR-ABL/
ABL≤12.7% (BCR-ABLIS≤10%); CCgR equivalence=BCR-ABL/ABL≤1.27% (BCR-ABLIS≤1%); and MMR=BCR-ABL/ABL≤0.127% (BCR-ABLIS≤0.1%)
§ Latest recommended starting dose for nilotinib 400 mg twice daily and dasatinib 100 mg once daily, respectively
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Patient No. Prior TKI therapy Disease phase at current TKI Indication for current 
TKI
Mutation status before current 
TKI
Best haematologic 
response†
Cytogenetic/molecular response‡ TKI mean dose 
intensity (mg/day)§
Days not on TKI (% 
of total duration)
Subsequent progression
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BCR-ABL/ABL: 65.3% (0 month) to MMR (24 months)
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BCR-ABL/ABL: 81.5% to 28.2% (10 months)
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Fold increase in IC50*
Imatinib Nilotinib Dasatinib
Wild type 1 1 1
M244V 7.69 2.92 1.63
L248V 3.54 2.80 5.11
G250E 6.86 4.56 4.45
Y253H 24.62 34.62 1.63
E255K 6.02 6.69 5.61
E255V 16.99 10.31 3.44
E279K 3.55 2.05 1.64
T315I 17.50 39.41 75.03
F317L 2.60 2.22 4.46
M351T 1.76 0.44 0.88
F359V 2.86 5.16 1.49
E459K NA NA NA
TABLE 3. In-vitro sensitivity of kinase domain mutants to 
various tyrosine kinase inhibitors as measured by IC50
20,27
* Results are expressed as fold increase compared with that of wild-
type BCR-ABL. IC50 values for imatinib, nilotinib, and dasatinib 
against wild-type BCR-ABL are 527 nM, 17.69 nM, and 1.83 nM 
respectively; relative resistance: ≤2 denotes sensitive, 2.01-4 
moderately resistant, 4.01-10 resistant, and >10 highly resistant; 
NA denotes not available
 Predicting responses in patients harbouring 
multiple KD mutations can be difficult, in particular 
those harbouring multiple mutants of discordant 
drug sensitivity. Again, the in-vitro drug sensitivity and 
the clinical response may not be concordant. Patient 
N2 showed concomitant nilotinib-sensitive M351T 
and -resistant G250E mutants. Major cytogenetic 
response was not reached and CHR was transient, 
lasting for only a period of 8 months. A repeated KD 
mutational analysis showed a shift in the pattern with 
the emergence of E255V and the disappearance of 
M351T and G250E. Patient N1 showed a concomitant 
nilotinib–highly resistant Y253H mutant, and an 
E459K mutant of unknown nilotinib sensitivity. Major 
cytogenetic response was reached after use of 
nilotinib, and BCR-ABLIS was reduced to 1.26% at 25 
months. In a phase II study, only one out of seven 
patients with a single mutant Y253H achieved MCgR.32 
Neither of the two patients with E459K achieved 
MCgR after nilotinib.32
Response to tyrosine kinase inhibitor in patients 
negative for kinase domain mutation
Thirteen patients were negative for the BCR-ABL KD 
mutation. The two patients with blastic disease (D18, 
N7) did not respond. All the rest showed CHR after 
salvage therapy. Major cytogenetic response was 
achieved in four patients (2 AP, 2 CP), of which two 
were complete, with one also reaching MMR.
 Published studies have found no differences 
in the overall cytogenetic and molecular responses 
of patients with and without KD mutations.32-34 We 
monitored the responses of our patients on dasatinib 
3- to 6-monthly by Taqman RQ-PCR. Reductions in 
the BCR-ABL transcripts were more readily seen in 
mutation-positive than mutation-negative patients 
(Fig). Most mutation-negative patients showed 
less than 1-log reduction in the BCR-ABL/ABL ratio. 
The higher dasatinib dose intensity that mutation-
positive patients could tolerate as opposed to 
mutation-negative patients (94.5 vs 51 mg), and the 
difference in the spectrum of mutations compared to 
published studies are probably the major reasons for 
the different responses.
Discussion
In in-vitro studies, T315I mutation is highly resistant 
to all three TKI agents available in Hong Kong. F317L, 
V299L, and T315A are mutations that are resistant 
to dasatinib, and P-loop (E255V/K, Y253H/F) and 
F359V mutations are resistant to nilotinib.20,35 In the 
management of imatinib resistance, the differential 
response of KD mutations to TKI can guide the 
clinical choice of alternative TKI agents or other 
therapies. Our experience and that of others support 
that F359V mutation predicts good responses to 
dasatinib even after nilotinib failure.36 The presence 
of the highly resistant T315I mutant predicts TKI 
failure, and allogenic BMT is recommended for 
suitable candidates. Patients with moderately drug-
resistant or resistant mutants may still be responsive 
to TKI agents, provided that a high enough dose level 
can be maintained. This is exemplified in our patients 
with E255K. The cytogenetic responder tolerated a 
higher standard dose of dasatinib than did the two 
non-cytogenetic responders. Using the IC90 value 
as a benchmark of clinical benefit, in-vitro studies 
projected that nilotinib at a trough level of 500 nmol/L 
would fail to suppress Y253H, E255V, and T315I 
mutants, while a trough level of 1.5 µmol/L (achievable 
by nilotinib 400 mg twice daily in pharmacokinetic 
studies) should suppress all mutants except T315I.20,35 
Dasatinib at a trough level of 50 nmol/L can also 
suppress all mutants except T315I.20,35
 There are studies supporting the superiority 
of dasatinib over nilotinib for controlling disease 
with P-loop mutants. In phase II studies, the CCgR 
rates after dasatinib were 40% for E255K/V and 69% 
for Y253H/F.37 None of the 13 patients with these 
mutants reached CCgR after nilotinib.32 In a study 
that monitored the dynamics of KD mutation after 
sequential TKI therapy, new mutations involving P-
loop, codons 311 and 359 accounted for more than 
half of the new mutations after nilotinib.21 On the 
other hand, F317L was the most prevalent emerging 
mutation after dasatinib therapy.21 As mutational 
patterns can change during TKI therapy, a repeated 
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KD mutational analysis is recommended whenever 
the response is suboptimal. That was done for patient 
N2 and we noted the switching of the mutational 
pattern from M351T and G250E to E255V associated 
with nilotinib failure. Patients with emerging P-loop 
mutants resistant to nilotinib may be responsive to 
Time of assay from dasatinib (months)
FIG.  Three- and six-monthly BCR-ABL/ABL ratios were monitored by real-time quantitative polymerase chain reaction in 17 patients on dasatinib. 
Results are shown as a log BCR-ABL/ABL ratio plotted against time in (a) mutation-positive and (b) mutation-negative patients
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